Sglt2 Inhibitor

Prescribing combination therapy to individuals with diabetes early in treatment could allow for better glycemic control and reduced odds of treatment failure, according to a speaker at the virtual Cardiometabolic Health Congress.

A keynote speech at the virtual Cardiometabolic Health Congress focused on advances in the use of genetics, artificial intelligence and SGLT2 inhibitors in cardiometabolic care. It was the top story in cardiology last week.

In recent years, cardiologists, endocrinologists and primary care physicians have observed marked advances in the use of genetics, artificial intelligence and SGLT2 inhibitors in cardiometabolic care, according to a keynote speech.

In the past year, numerous drugs and interventions have addressed diabetes, obesity, and cardiometabolic health, according to presentations at the virtual Cardiometabolic Health Congress.

We know that obesity prevalence continues to increase, that metabolic syndrome follows and a higher incidence of type 2 diabetes is now before us.

The European Society of Cardiology Congress was, for the first time, held virtually. From Aug. 29 to Sept. 1, the digital experience drew virtual attendees from around the world, to watch and hear the latest on topics ranging from the benefits of SGLT2 inhibition in patients without diabetes to the first randomized trial on the question of whether to stop ACE inhibitors and angiotensin receptor blockers in patients with COVID-19.

Trials of SGLT2 inhibitors and GLP-1 receptor agonists, typically treatments for type 2 diabetes, have demonstrated potential CV and kidney benefits , according to a scientific statement from the American Heart Association.

Healio and Cardiology Today have curated a list of the top-read news from the virtual Heart in Diabetes CME Conference.

New exploratory analyses show treatment with the SGLT2 inhibitor ertugliflozin reduced risk for worsening kidney function, dialysis or renal death among adults with type 2 diabetes compared with placebo.

Treatment with dapagliflozin significantly reduced renal failure, cardiovascular death or hospitalization for heart failure, and prolonged survival among adults with chronic kidney disease with and without type 2 diabetes, study data show.